StratDeck

Two stocks in Healthcare

Amgen vs Medtronic: profit, growth, debt and price compared

Medtronic is stronger on 5 of 7 figures: sales growth, debt, price for its expected profit, dividend and analysts' view. Amgen is stronger on 2: profit margin and price trend.

Figures as of 18 November 2026SEC EDGARYahoo Finance

Save both stocks to your watchlist and revisit their latest fundamentals.

Amgen and Medtronic side by side
AmgenAMGNMedtronicMDT
Net marginStronger: 24.1%13.9%
Revenue growth, past year+8.45%Stronger: +13.73%
Debt to equity376.3%Stronger: 55.4%
Forward P/E17.7×Stronger: 15.7×
Dividend yield2.27%Stronger: 2.83%
AnalystsHold · 29Stronger: Buy · 26
From its 200-day averageStronger: +14.8%+12.5%

Share price over the past year

  • Amgen+29.0%
  • Medtronic−0.1%

18 Nov 202518 Nov 2026

Amgen or Medtronic: which is stronger?

  • AMGN

    Which is more profitable?

    Amgen keeps more of each sale as profit: 24.1% against 13.9%.

  • MDT

    Which is growing its sales faster?

    Medtronic is growing its sales faster: +13.73% over the past year, against +8.45%.

  • MDT

    Which has borrowed less?

    Medtronic has borrowed less: its debt is 55.4% of what its shareholders own, against 376.3% for Amgen.

  • MDT

    Which costs less for the profit it is expected to make?

    Medtronic costs less for the profit it is expected to make: 15.7× its forward earnings, against 17.7×.

  • MDT

    Which pays more in dividends?

    Medtronic pays more back in dividends for what a share costs: 2.83% a year, against 2.27%.

  • MDT

    Which do analysts rate higher?

    Analysts are warmer on Medtronic: Buy, against Hold for Amgen.

  • AMGN

    Which is in the stronger price trend?

    Amgen's price is in the stronger trend: 14.8% above its 200-day average, against 12.5% above.

What each company does

AMGNAmgen

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.

Reports results on 2 February 2027

MDTMedtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally.

Reports results on 24 November 2026

This comparison is just the starting point.

Discover opportunities, understand companies and compare investments in one place. See how StratDeck works

Keep researching

Where next

Every US healthcare comparison

Free email

Up to speed in minutes, four times a week

Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.

Early access

Become a StratDeck founding user

Use StratDeck, tell us what's missing, and help decide what we build next.

100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.